Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Ophthalmological Medicine
Volume 2016 (2016), Article ID 1926178, 4 pages
http://dx.doi.org/10.1155/2016/1926178
Case Report

Photopsias during Systemic Bevacizumab Therapy

Department of Ophthalmology, New York University School of Medicine, New York, NY 10016, USA

Received 21 December 2015; Accepted 28 February 2016

Academic Editor: Maurizio Battaglia Parodi

Copyright © 2016 Heather Leisy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Ferrara, K. J. Hillan, and W. Novotny, “Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy,” Biochemical and Biophysical Research Communications, vol. 333, no. 2, pp. 328–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Michels, P. J. Rosenfeld, C. A. Puliafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. W. L. Ho, H. Wong, and T. Yau, “The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?” Acta Ophthalmologica, vol. 91, no. 7, pp. 604–609, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. B. K. Yildiz, S. Ozdek, U. Demirci et al., “Functional and morphological effects of systemic bevacizumab on cancer patients' eyes,” Optometry and Vision Science, vol. 92, no. 1, pp. 102–106, 2015. View at Publisher · View at Google Scholar
  6. S. Biswas, J. Wrigley, C. East et al., “A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update,” Ecancermedicalscience, vol. 2, article 108, 2008. View at Publisher · View at Google Scholar
  7. J. H. Sherman, D. G. Aregawi, A. Lai et al., “Optic neuropathy in patients with glioblastoma receiving bevacizumab,” Neurology, vol. 73, no. 22, pp. 1924–1926, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. I. Van Der Reis, E. C. La Heij, Y. De Jong-Hesse, P. J. Ringens, F. Hendrikse, and J. S. A. G. Schouten, “A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections,” Retina, vol. 31, no. 8, pp. 1449–1469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Biagi, V. Conti, N. Montanaro et al., “Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions,” European Journal of Clinical Pharmacology, vol. 70, no. 12, pp. 1505–1512, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. World Health Organization, The Use of the WHO-UMC System for Standardized Case Causality Assessment, Uppsala Monitoring Centre, Uppsala, Sweden, 2005.
  11. X. Zhu, S. Wu, W. L. Dahut, and C. R. Parikh, “Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis,” American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186–193, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Hapani, A. Sher, D. Chu, and S. Wu, “Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis,” Oncology, vol. 79, no. 1-2, pp. 27–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. F. Mulcahy and A. B. Benson III, “Bevacizumab in the treatment of colorectal cancer,” Expert Opinion on Biological Therapy, vol. 5, no. 7, pp. 997–1005, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Nishijima, Y.-S. Ng, L. Zhong et al., “Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury,” The American Journal of Pathology, vol. 171, no. 1, pp. 53–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Wang, O. M. Xiao, L. Xie et al., “Vascular endothelial growth factor overexpression delays neurodegeneration and prolongs survival in amyotrophic lateral sclerosis mice,” The Journal of Neuroscience, vol. 27, no. 2, pp. 304–307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Heiduschka, H. Fietz, S. Hofmeister et al., “Penetration of bevacizumab through the retina after intravitreal injection in the monkey,” Investigative Ophthalmology and Visual Science, vol. 48, no. 6, pp. 2814–2823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Kim, R. N. Fariss, C. Zhang, S. B. Robinson, M. Thill, and K. G. Csaky, “Mapping of the neonatal fc receptor in the rodent eye,” Investigative Ophthalmology and Visual Science, vol. 49, no. 5, pp. 2025–2029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Sallinen, T. Heikura, J. Koponen et al., “Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer,” BMC Cancer, vol. 14, article 696, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Qaum, Q. Xu, A. M. Joussen et al., “VEGF-initiated blood-retinal barrier breakdown in early diabetes,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2408–2413, 2001. View at Google Scholar · View at Scopus
  20. H. Verheul, S. Paesante, J. Jaspers, H. Hammers, B. Salumbides, and R. Pili, “VEGF pharmacodynamics during bevacizumab treatment,” Journal of Clinical Oncology, vol. 26, no. 15, article 14633, 2008. View at Google Scholar
  21. M. Saint-Geniez, A. S. R. Maharaj, T. E. Walshe et al., “Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors,” PLoS ONE, vol. 3, no. 11, Article ID e3554, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. G. C. Brown, M. M. Brown, and D. H. Fischer, “Photopsias: a key to diagnosis,” Ophthalmology, vol. 122, no. 10, pp. 2084–2094, 2015. View at Publisher · View at Google Scholar
  23. H. G. T. Blaauwgeers, G. M. Holtkamp, H. Rutten et al., “Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation,” American Journal of Pathology, vol. 155, no. 2, pp. 421–428, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Peters, P. Heiduschka, S. Julien et al., “Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab,” American Journal of Ophthalmology, vol. 143, no. 6, pp. 995.e2–1002.e2, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. E. Fung, P. J. Rosenfeld, and E. Reichel, “The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide,” British Journal of Ophthalmology, vol. 90, no. 11, pp. 1344–1349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Higashide, E. Murotani, Y. Saito, S. Ohkubo, and K. Sugiyama, “Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 4, pp. 603–610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Reimann, G. Folprecht, R. Haase et al., “Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study,” Experimental and Translational Stroke Medicine, vol. 5, no. 1, article 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Klastersky, “Adverse effects of the humanized antibodies used as cancer therapeutics,” Current Opinion in Oncology, vol. 18, no. 4, pp. 316–320, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Francis, Atlantic Coast Retinal Club and Macula Society 2016, Crizotinib-Associated Posterior Vitreous Detachment, New York, NY, USA, 2016.
  30. F. Forooghian, P. J. Kertes, K. T. Eng, E. Agrón, and E. Y. Chew, “Alterations in the intraocular cytokine milieu after intravitreal bevacizumab,” Investigative Ophthalmology and Visual Science, vol. 51, no. 5, pp. 2388–2392, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Mozayan and S. Farah, “Acute anterior uveitis following intravitreal injection of bevacizumab,” Ophthalmic Surgery Lasers and Imaging, vol. 44, no. 1, pp. 25–27, 2012. View at Publisher · View at Google Scholar · View at Scopus